Please login to the form below

Not currently logged in
Email:
Password:

Tresiba

This page shows the latest Tresiba news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

80bn krone on price reductions, competition from generic long-acting insulins including insulin glargine, and cannibalisation by Novo Nordisk’s newer insulin product Tresiba (insulin degludec).

Latest news

More from news
Approximately 31 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Harnessing commercial innovation Harnessing commercial innovation

    products - such as basal insulin Tresiba and its Ryzodeg and Xultophy combinations. “

  • Interview: Peter Meeus, Novo Nordisk Interview: Peter Meeus, Novo Nordisk

    Not reporting it is a very big issue.”. Novo has attempted to address hypoglycaemia with the launch of its new insulin Tresiba (insulin degludec), which was approved in Europe at the ... Tresiba has also demonstrated it is just as effective even when

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics